Robert Sealand, MD
Internal Medicine · Mechanicsville, VANPI 1093976227
Payments from drug & device makers
Across 183 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$458
- Abbott$438
- Insulet Corporation$393
- Novo Nordisk$251
- Dexcom, Inc.$229
- AstraZeneca$228
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,707100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $458 |
| Abbott | 24 | $438 |
| Insulet Corporation | 9 | $393 |
| Novo Nordisk | 14 | $251 |
| Dexcom, Inc. | 8 | $229 |
| AstraZeneca | 15 | $228 |
| Sanofi-aventis U.S. LLC | 9 | $195 |
| Corcept Therapeutics | 6 | $113 |
| Xeris Pharmaceuticals, Inc. | 5 | $105 |
| Amgen(2 entities) | 6 | $101 |
| Antares Pharma, Inc. | 5 | $101 |
| Amneal Pharmaceuticals LLC | 5 | $87 |
| Boehringer Ingelheim | 4 | $87 |
| Bayer | 3 | $77 |
| Pfizer | 4 | $72 |
| Medtronic(2 entities) | 4 | $64 |
| BETA Bionics, Inc. | 3 | $61 |
| Lifescan, Inc. | 2 | $51 |
| Tandem Diabetes Care, Inc. | 2 | $49 |
| Shire North American Group Inc | 3 | $47 |
| Cequr Corporation | 3 | $45 |
| Recordati_rare_diseases_inc. | 2 | $44 |
| Embecta Corp. | 1 | $41 |
| Valeritas, Inc. | 2 | $35 |
| Merck | 3 | $35 |
| IBSA Pharma Inc. | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $32 |
| Sequel Med Tech, LLC | 1 | $29 |
| Johnson & Johnson | 2 | $29 |
| Radius Health, Inc. | 2 | $28 |
| BD | 1 | $24 |
| Eisai Inc. | 1 | $23 |
| AbbVie | 1 | $23 |
| Novartis | 1 | $22 |
| Halozyme Inc | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Aytu Biopharma, Inc. | 1 | $15 |
How this compares
$3,716 in reported general payments places this provider in the 85th percentile of 2,724 internal medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 207 | $289,880 |
| TrulicityDulaglutide | 246 | $287,592 |
| JardianceEmpagliflozin | 165 | $199,909 |
| MounjaroTirzepatide | 138 | $171,020 |
| JanuviaSitagliptin Phosphate | 104 | $86,563 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $83,670 |
| FarxigaDapagliflozin Propanediol | 73 | $77,800 |
| Tresiba Flextouch U-100Insulin Degludec | 79 | $62,491 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 287 | $58,054 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 48 | $49,698 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $46,544 |
| RybelsusSemaglutide | 29 | $36,891 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 56 | $29,690 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $24,275 |
| Humalog Kwikpen U-100Insulin Lispro | 59 | $22,900 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Lyumjev, Humulin 70-30, Humulin N | $458 | $482,325429 claims |
| Novo NordiskOzempic, Rybelsus | $251 | $326,772236 claims |
| Boehringer IngelheimJardiance | $87 | $199,909165 claims |
| MerckJanuvia, Janumet | $35 | $97,292116 claims |
| AstraZenecaFarxiga | $228 | $77,80073 claims |
| Antares Pharma, Inc.Xyosted | $101 | $9,25214 claims |
| AbbVieSynthroid | $23 | $7,25895 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $87 | $4,706487 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Mechanicsville
- Kumar AbhishekMechanicsville$1M
- Leroy VaughanRichmond$20.8M
- James ClarkCharlottesville$16.2M
- Nabil AndrawisBurke$8.5M
- Mary BlumbergNorfolk$6.5M
- David RamstadSuffolk$5.8M
- Andrew PoklepovicRichmond$4.6M
- Nashwa GabraBurke$4.3M
- Michael DevittCharlottesville$3.5M
- Richard JacksonRichmond$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.